Sentence examples for develop a dose from inspiring English sources

Therefore, our objective was to develop a dose selection method for PK studies in hemodialysis patients using the simulation-extrapolation of an optimal PK dose from the PK parameters of a subpharmacological dose.

Female MRL+/+ mice treated for 40 weeks with drinking water containing concentrations of trichloroacetaldehyde hydrate that encompassed the molar equivalents of previous low-level trichloroethylene exposure did not develop autoimmune hepatitis or lupus nephritis but did develop a dose-dependent alopecia and skin inflammation (Blossom et al. 2007).

To develop a dosing guideline that accounts for variation in each of these parameters as well as in RRT modalities and settings, a large multicenter RRT pharmacokinetic study is required.

In addition, the International Warfarin Pharmacogenetics Consortium [ 28] has pooled genetic data relating to warfarin from researchers worldwide to develop a dosing algorithm that will be more applicable to a range of different ethnic groups.

The aim of this study was to develop a dosing nomogram for the administration of vancomycin by continuous infusion for the first 24 hours of therapy based on the measured urinary creatinine clearance (8 h CLCR).

The aim of this study was to develop a dosing nomogram for the administration of vancomycin by CI for the first 24 h of therapy based on an 8-h measured urinary creatinine clearance (8 h CLCR); and second, to evaluate its efficiency in a separate cohort of critically ill septic patients.

We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF.

The MTD was defined as the dose at which three or more out of six patients developed a dose limiting toxicity.

Specifically, our study power was enhanced by selecting a genetically enriched study population predisposed to breast cancer, by using a counter-matched design, and by developing a dose reconstruction method to reduce the error in estimating individual radiation exposure derived from imperfect and old medical records.

We have previously developed a dose-dependent glycan array binding assay [10], [21] to quantitatively characterize glycan receptor binding affinity of HA by calculating an apparent binding constant Kd'.

No patient developed a dose-limiting toxicity.